IDEC-C2B8 chimeric anti-CD20 antibody (MAB): Safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL)

被引：0
|
作者：
GrilloLopez, AJ [1 ]
Varns, C [1 ]
Waldichuk, C [1 ]
Dallaire, BK [1 ]
Rosenberg, J [1 ]
McClure, A [1 ]
Shen, D [1 ]
机构：
[1] IDEC PHARMACEUT CORP,SAN DIEGO,CA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1996年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1072 / 1072
页数：1
相关论文
共 50 条
  • [1] Anti-CD20 chimeric antibody, IDEC-C2B8: Safety and clinical activity in the treatment of relapsed low grade or follicular (IWF:A-D) lymphomas (LG-F/NHL).
    GrilloLopez, AJ
    Dallaire, BK
    Varns, C
    Leonard, JE
    Shen, D
    McClure, A
    Rogers, J
    Rosenberg, J
    Wei, A
    Shuey, S
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 691 - 691
  • [2] Pharmacokinetics (PK) and pharmacodynamics (PD) of the anti-CD20 antibody (MAB) IDEC-C2B8 in patients (PTS) with relapsed low-grade or follicular lymphoma (LG/F NHL).
    McLaughlin, P
    Cabanillas, F
    GrilloLopez, AJ
    Link, GL
    Levy, R
    Cruczman, M
    Heyman, MR
    Williams, M
    Jain, V
    BenceBruckler, L
    Ho, AD
    Lister, J
    Wey, K
    Shuey, S
    Parker, E
    BLOOD, 1996, 88 (10) : 350 - 350
  • [3] IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
    Maloney, DG
    GrilloLopez, AJ
    White, CA
    Bodkin, D
    Schilder, RJ
    Neidhart, JA
    Janakiraman, N
    Foon, KA
    Liles, TM
    Dallaire, BK
    Wey, K
    Royston, I
    Davis, T
    Levy, R
    BLOOD, 1997, 90 (06) : 2188 - 2195
  • [4] Clinical activity of the monoclonal antibody (MAB) IDEC-C2B8 in patients (pts) with relapsed low-grade or follicular NHL (R-LG/F NHL)
    GrilloLopez, AJ
    White, CA
    Dallaire, BK
    Varns, C
    Shen, CD
    Weaver, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1179 - 1179
  • [5] IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with pretreated low-grade non-Hodgkin's lymphoma.
    Schwandt, KU
    Bremer, K
    ANNALS OF ONCOLOGY, 2000, 11 : 105 - 105
  • [6] IDEC-C2B8 anti-CD20 antibody: Final report on a phase III pivotal trial in patients (PTS) with relapsed low-grade or follicular lymphoma (LG/F NHL).
    McLaughlin, P
    Cabanillas, F
    GrilloLopez, AJ
    Link, BK
    Levy, R
    Cruczman, M
    Heyman, MR
    Williams, M
    Jain, W
    BenceBruckler, I
    Ho, AD
    Lister, J
    Rosenberg, J
    Dallaire, BK
    Shen, D
    BLOOD, 1996, 88 (10) : 349 - 349
  • [7] Review of single agent IDEC-C2B8 safety and efficacy results in low-grade or follicular non-hodgkin's lymphoma (NHL)
    White, CA
    GrilloLopez, AJ
    Maloney, D
    Bodkin, D
    Czuczman, M
    McLaughlin, P
    Cabanillas, F
    Saven, A
    Saleh, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 91 - 91
  • [8] Pharmacokinetics (PK) of the chimeric anti-CD20 antibody (MAB) IDEC-C2B8: Analysis of serum concentrations in patients (PTS) with relapsed B-cell lymphoma
    Rosenberg, J
    Waldichuk, C
    GrilloLopez, AJ
    Leonard, JE
    Dallaire, BK
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1071 - 1071
  • [9] Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma
    Klemens Scheidhauer
    Ingo Wolf
    Hans-Joachim Baumgartl
    Christoph von Schilling
    Burkhard Schmidt
    Günther Reidel
    Christian Peschel
    Markus Schwaiger
    European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29 : 1276 - 1282
  • [10] Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma
    Scheidhauer, K
    Wolf, I
    Baumgartl, HJ
    von Schilling, C
    Schmidt, B
    Reidel, G
    Peschel, C
    Schwaiger, M
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (10) : 1276 - 1282
12345